Apnimed
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
39 John F. Kennedy St Fl 4, Cambridge, M...Phone Number
(877) 276-4633Website
www.apnimed.comRevenue
$20.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
3
1
1
About Apnimed
Apnimed is a clinicalstage biopharmaceutical company focused on discovering, developing and commercialising novel oral therapies for sleeprelated breathing diseases, especially obstructive sleep apnea (OSA). Its lead investigational drug candidate, AD109, is designed to address the underlying neuromuscular dysfunction that contributes to airway collapse during sleep, with the goal of offering a simpler treatment option to devices or surgery. The company emerged from research and aims to expand effective diagnosis and treatment reach for people living with OSA and similar conditions.Apnimed is seen as an innovative clinicalstage biotech in sleep medicine, generating strategic collaborations and funding to support latestage clinical development and potential regulatory submissions.Explore more
Apnimed Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apnimed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Apnimed has recently received funding, and reach out quickly before it becomes old news!
Apnimed, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Apnimed
Funding: Get notified immidiatlly once Apnimed has new funding data
Check out if Apnimed is spiking on competitors!
Product Launch: Get notified when Apnimed launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Apnimed recently announced quarterly report
Click to see if Apnimed had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Apnimed
Compare insights from companies similar to Apnimed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Apnimed is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Apnimed is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Apnimed.
Apnimed financials insights
Gather financial insights about Apnimed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$15M
2021
Series B
$25M
2023
Series C
$142.3M
2025
Debt
$23M
2026
Private Equity
$25M
Debt
$150M
Apnimed Tech Stack
A closer look at the technologies used by Apnimed
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Apnimed is planning to move offices in August 2026. The move will impact approximately 83 employees at the existing office located at 39 John F. Kennedy St., 4th Floor, Cambridge, MA.
Facilities Relocation/Expansion
Funding
Funding
Funding
Funding
Person-Based
Person-Based
Apnimed News & Media
Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
CAMBRIDGE, Mass., June 10, 2026 /PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that six...Apnimed Appoints Experienced Pharmaceutical Executive Kevin R. Lind as Chief Executive Officer to Implement Next Phase of Growth Strategy
Mr. Lind succeeds Company founder Lawrence G. Miller, MD, who is transitioning to Vice Chair of the Board Mr. Lind brings significant prior CEO, commercial, financial and capital markets experience, including leading Longboard Pharmaceuticals to an acquisition by H. Lundbeck A/S for...Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine
Companion mechanistic review article published concurrently in the American Journal of Respiratory Cell and Molecular Biology in first-of-its-kind dual publications Publications reinforce AD109's potential, if approved, as a first-in-class oral pill designed to improve oxygenation during...Apnimed Announces Three Oral Presentations and a Late-breaking Poster at the American Thoracic Society (ATS) 2026 International Conference
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced multiple...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Apnimed
Sign Up For FreeTo access detailed company insights
Apnimed is a clinicalstage biopharmaceutical company focused on discovering, developing and commercialising novel oral therapies for sleeprelated breathing diseases, especially obstructive sleep apnea (OSA). Its lead investigational drug candidate, AD109, is designed to address the underlying neuromuscular dysfunction that contributes to airway col... Read More
